BLBo-In Lee

Bo-In Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bo-In Lee has a total of 307 co-authors. Here are the top co-authors by number of shared publications:

  • Han Hee Lee

    Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    19 shared publications
  • Myung-Gyu Choi

    Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

    18 shared publications
  • Jae Myung Park

    The Catholic University of Korea College of Medicine, Seoul, Korea (the Republic of)

    12 shared publications
  • Hwang Choi

    Division of Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

    11 shared publications
  • Young-Seok Cho

    Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

    11 shared publications
  • Byung-Wook Kim

    Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

    7 shared publications

Latest Publications

  • Open Access

    Vimentin neutralizing antibody ameliorate inflammatory bowel disease by inhibiting fibrosis and inflammatory cell death

    by Sol Kim, Hye Yeon Kang, Jin-Sil Park, JeongWon Choi, Ha Yeon Jeong, Seon Yeong Lee, Han Hee Lee, Bo-In Lee, Mi-La Cho

    Background: Inflammatory bowel disease (IBD) is characterized by chronic inflammation intertwined with fibrosis and increased necroptosis. Vimentin, an intermediate filament protein closely associated with fibrosis and several inflammatory pathways, is elevated in IBD tissues. We conducted experiments to determine the effect of neutralization of extracellular vimentin with an anti-vimentin antibody (Ab) on the pathogenesis of IBD. Methods: IBD was mimicked in a 7-week C57BL6 mice by mixing 3% dextran sodium sulfate (DSS) in autoclaved drinking water for five days. A nti-vimentin Ab was intraperitoneally injected with a concentration of 3 milligrams per kilogram repeatedly in a three-day interval simultaneously with DSS administration. Results: In dextran sodium sulfate (DSS)-induced colitis mice, the anti-vimentin Ab decreased the levels of total and cell-surface vimentin in colon tissues compared to control-treated mice. In DSS-induced colitis mice, treatment with the anti-vimentin Ab improved body weight loss and colon shortening, thereby reducing the severity of DSS-induced colitis. In addition, the anti-vimentin Ab reduced the number of cells expressing fibrosis markers, inflammatory cytokines, and necroptotic markers in colon tissues of DSS-induced colitis mice. In CCD-18CO human colon epithelial cells, the increases in the levels of fibrosis markers caused by TGFβ were enhanced by vimentin protein stimulation and the anti-vimentin Ab reduced the levels of fibrosis-related factors. Conclusion: This is the first report of the therapeutic effect of an anti-vimentin Ab on the pathogenic mechanisms of IBD. Further studies are needed to confirm its therapeutic potential in clinical settings.

  • Efficacy and Safety of 1‐L Polyethylene Glycol With Low Ascorbic Acid for Bowel Preparation: A Randomized Clinical Trial

    by Ji Eun Baek, Hyo Suk Kim, Sung Hoon Jung, Sang‐Bum Kang, Bo‐In Lee, Kang‐Moon Lee

    Background and Aims: Ultra‐low‐volume polyethylene glycol (PEG) with ascorbic acid (Asc) improves tolerability, but Asc‐related gastrointestinal and metabolic adverse events remain a concern. Whether reducing the Asc dose preserves cleansing efficacy without compromising safety is unclear. We compared a modified 1‐L PEG regimen with reduced Asc (1‐L PEG + low Asc) with standard 1‐L PEG + Asc and 2‐L PEG + Asc formulations. Methods: In this multicenter, randomized, investigator‐blinded, three‐arm noninferiority trial across five hospitals, low‐risk adults undergoing colonoscopy were allocated (1:1:1) to 1‐L PEG + low Asc, 1‐L PEG + Asc, or 2‐L PEG + Asc. The primary endpoint was successful bowel cleansing by the Harefield Cleansing Scale (HCS). Secondary endpoints included Boston Bowel Preparation Scale (BBPS), endoscopic outcomes, gastric residual volume quantified by esophagogastroduodenoscopy, patient‐reported tolerability, and adverse events. Results: Among 242 per‐protocol participants, HCS‐defined successful cleansing was achieved in 92.7% with 1‐L PEG + low Asc, 100.0% with 1‐L PEG + Asc, and 98.7% with 2‐L PEG + Asc ( p = 0.01). The low‐Asc regimen met noninferiority criteria versus both comparators (risk difference vs. 1‐L PEG + Asc, −7.3%; 97.5% CI, −13.0 to −1.6). BBPS‐defined success, adenoma detection rate (31.7%, 18.1%, and 20.8%), gastric fluid volume (27.4, 28.2, and 25.2 mL), and willingness to repeat the regimen (78.0%, 73.5%, and 71.4%) were similar across groups. Adverse‐event rates were comparable, with no electrolyte disturbances or renal events observed. Conclusions: A modified 1‐L PEG regimen with reduced Asc provides bowel cleansing efficacy noninferior to both standard 1‐L and 2‐L PEG + Asc preparations, with comparable tolerability and safety.

  • Open Access

    Serum REG3α as a biomarker for clinical and endoscopic activity in ulcerative colitis

    by Seung-Jun Kim, Bo-In Lee, Mi-La Cho, Jin-Sil Park, SeungCheon Yang, Han Hee Lee, Kang-Moon Lee, Jeong-Seon Ji, Eun-Jee Oh, Sung-Hwan Park

    Current biomarkers, including serum C-reactive protein (CRP) and fecal calprotectin, have limitations in monitoring disease activity of ulcerative colitis (UC). Regenerating islet-derived protein 3α (REG3α), which is constitutively produced by Paneth cells, is a bactericidal C-type protein against Gram-positive bacteria. Preliminary studies suggest that REG3α may serve as a promising novel blood-based biomarker for assessing disease activity in patients with UC. A total of 128 patients with UC were prospectively enrolled. Blood samples were obtained on the same day as endoscopy. Serological markers including REG3α, CRP, albumin, and serum calprotectin were measured. The clinical and endoscopic activity were assessed using the total Mayo score (remission, mild, or moderate-to-severe) and the Mayo endoscopic subscore (MES), respectively. Serum levels of REG3α, CRP, albumin, and calprotectin were significantly correlated with clinical activity (Mayo score ≥ 6) (Spearman's ρ = 0.362, P < 0.001; ρ = 0.429, P < 0.001; ρ = -0.312, P < 0.001; and ρ = 0.253, P = 0.004, respectively). Serum levels of REG3α, CRP, and albumin were also significantly correlated with endoscopic activity (MES ≥ 2) (ρ = 0.362, P < 0.001; ρ = 0.420, P < 0.001; and ρ = -0.240, P = 0.006, respectively), whereas serum calprotectin was not (ρ = 0.147, P = 0.098). The combination of serum REG3α and CRP predicted clinical and endoscopic activity with AUC values of 0.847 and 0.783, respectively, showing improved discriminatory performance compared with the individual biomarkers in this cohort. Among 19 patients who underwent serial follow-up of REG3α levels, a significant decrease was observed during periods of clinical improvement (P = 0.005), although this finding should be interpreted as preliminary. REG3α is a promising blood-based biomarker associated with both clinical and endoscopic activity in UC. When interpreted together with CRP, it showed improved discriminatory performance in this cohort. This serum-based approach may be useful as an adjunctive option when stool-based testing is less feasible. However, the combined REG3α-CRP model should be considered exploratory, and the serial monitoring findings should be interpreted as preliminary. Further validation in larger, independent cohorts, including direct comparison with fecal calprotectin, is required before broader clinical application can be considered.

  • Open Access

    Latilactobacillus curvatus DCF0620 and postbiotics derived from soybean germ reduce colitis severity by modulating fibrosis and gut dysbiosis

    by Jin-Sil Park, Hye Yeon Kang, JeongWon Choi, Wonjong Lee, Hyunbin Seong, Sang Hee Cho, Su Beom Lee, Nam Soo Han, Jaekwon Choi, Bo-In Lee, et al.

    Background: Given that microbiota dysbiosis is closely linked to the initiation and progression of inflammatory bowel disease (IBD), extensive research is underway to utilize beneficial probiotics as a therapeutic strategy for IBD. In this study, we compared the therapeutic efficacy of Lacticaseibacillus paracasei ( L. paracasei ) DCF0420, Lactiplantibacillus plantarum ( L. plantarum ) DCF0514, and Latilactobacillus curvatus ( L. curvatus ) DCF0620 and also investigated the potential of soybean germ-based postbiotics from DCF0620 as a treatment for IBD. Methods: Live L. paracasei DCF0420, L. plantarum DCF0514, L. curvatus DCF0620, or postbiotics were orally administered to DSS-induced colitis mice starting 7 days before DSS injection until the end of the experiment. Weight changes and the disease activity index were evaluated to assess disease severity. Inflammation and fibrosis were analyzed pathologically in intestinal tissue. Fecal samples from mice injected with postbiotics were subjected to 16S rRNA gene sequencing. Cytokine levels in spleen cell culture supernatants were measured by ELISA, and fibronectin levels in CCD-18Co cells were analyzed by Western blot. Results: Treatment with L. paracasei DCF0420, L. plantarum DCF0514, or L. curvatus DCF0620 increased the production of IL-10 in murine splenocytes in a dose-dependent manner under stimulation with anti-CD3 antibody or LPS. Furthermore, administration of each probiotic strain reduced the levels of fibronectin induced by TGF-β in CCD-18Co cells. In the DSS-induced colitis murine model, administration of L. curvatus DCF0620 effectively attenuated disease severity. Mechanistically, L. curvatus DCF0620 treatment controlled the infiltration of cells that express pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-17) and fibrotic markers (TGF-β, Col1, and α-SMA) into the intestinal tissue of DSS-induced colitis mice. Notably, administration of soybean germ-based postbiotics derived from L. curvatus DCF0620 also demonstrated therapeutic efficacy in the DSS-induced colitis mice, specifically by improving the dysbiosis observed in the colitis mice. Conclusion: Our findings suggest that L. curvatus DCF0620 and its soybean germ-based postbiotics represent promising therapeutic agents for IBD by demonstrating potent anti-inflammatory, anti-fibrotic, and gut microbiota-modulating effects.


  • Open Access

    CRIF1 gene therapy ameliorates inflammatory bowel disease by suppressing TH17 cells and fibrosis through mitochondrial function regulation

    by Jin-Sil Park, Hye Yeon Kang, Ha Yeon Jeong, SeungCheon Yang, JeongWon Choi, Sang Hee Cho, Sol Kim, Bo-In Lee, Mi-La Cho

    Background: CR6-interacting factor 1 (CRIF1) is a nuclear transcriptional regulator and a mitochondrial inner membrane protein. Although serious modifications of the tissue architecture of the small intestine have been reported in CRIF1-deficient mice, how this may affect the development of inflammatory bowel disease (IBD) remains unclear. We investigated the effects of CRIF1 on mice with colitis.Methods: In DSS-induced colitis mice administered p3XFLAG-CMV-10-CRIF1, clinical symptoms were evaluated. Mitochondrial morphology in the intestinal tissues of colitis mice and UC patients was observed by electron microscopy. Level of CRIF1 in the splenic mitochondria of colitis mice or human PBMCs were investigated by western blot or real-time PCR, and the amount of IL-17 in the supernatant of healthy PBMCs co-cultured with CRIF1-overexpressing mitochondria was investigated by ELISA.Results: Overexpression of CRIF1 attenuated the severity of colitis, alleviated weight loss, and intestinal shortening. Moreover, overexpression of CRIF1 significantly reduced the levels of proinflammatory and necroptosis-related factors in colon and inhibited intestinal fibrosis. The intestines of these mice showed a reduced level of CRIF1 and altered mitochondrial morphology. Transplantation of CRIF1-overexpressed mitochondria into mice with colitis alleviated disease severity. Patients with ulcerative colitis exhibited decreased CRIF1 levels with dysfunctional mitochondria in inflamed colonic tissue. CRIF1-overexpressing mitochondria inhibited IL-17 production in PBMCs from healthy control.Conclusion: Our findings demonstrate that CRIF1 alleviates IBD by suppressing inflammation and fibrosis by improving mitochondrial function. Improving mitochondrial function through CRIF1 may be a potential therapeutic strategy for IBD.


  • Optimal Timing of Surgery After Insertion of Self‐Expandable Metallic Stent to Obstructive Colorectal Neoplasm as a Bridge to Surgery

    by Dong Hyun Kim, Hyun Lim, Jung‐Wook Kim, Yunho Jung, Hyun‐Soo Kim, Ki‐Hyun Kim, Jin Won Kim, Young‐Eun Joo, Bo‐In Lee, Han Hee Lee

    Background and Aims: Colonic stenting using self‐expandable metallic stents (SEMS) as a bridge to surgery offers an effective alternative to emergency surgery for the management of malignant colorectal obstruction. However, the optimal timing of elective surgery after stenting remains controversial.Methods: This retrospective multicenter cohort study analyzed 380 patients with obstructive colorectal cancer who were treated with SEMS as a bridge to surgery. Patients were categorized into four groups based on the time from stent insertion to surgery: within 7 days, 8–14 days, 15–21 days, and 22 days or more.Results: The study cohort had a slight male predominance (55.8%), with an average age of 65.8 years. Most surgeries (74.2%) were laparoscopically performed. No significant differences were observed in stoma formation rates or postoperative complications between the different timing groups. Similarly, recurrence‐free survival, overall survival, locoregional recurrence, and distant metastasis rates showed no significant variations with the timing of post‐stenting surgery. A restricted cubic spline curve indicated that surgery within the 15–21‐day period post‐SEMS insertion resulted in the lowest incidence of stoma formation.Conclusions: Delaying elective surgery for up to 3 weeks post‐SEMS placement for obstructive colorectal cancer is recommended, particularly within the 15–21‐day period, to minimize stoma formation rates without compromising on long‐term outcomes.


  • Impact of perforation following self-expandable metal stent as a bridge to surgery for malignant colorectal obstruction: a multicenter study of the Research Group for Stent in the Korean Society of Gastrointestinal Endoscopy

    by Han Hee Lee, Dong Hyun Kim, Hyun Lim, Jung-Wook Kim, Yunho Jung, Hyun-Soo Kim, Hyung-Hoon Oh, Jin Won Kim, Kwang Bum Cho, Young-Eun Joo, et al.

    Background and aims Self-expandable metal stents (SEMS) are effective in alleviating malignant colorectal obstruction. However, bowel perforation following SEMS placement remains a significant concern, as it can adversely affect oncological outcomes. This study aimed to evaluate the recurrence and overall survival rates associated with SEMS-related bowel perforations. Methods This multicenter, retrospective analysis included patients with obstructive colorectal cancer who underwent SEMS placement as a bridge to surgery. The data collection period spanned from January 2008 to May 2019, with patient matching in a 1:5 ratio based on age, sex, tumor location, pathological stage, and achievement of curative resection. Results Among the 412 patients who received SEMS placement, 25 (6.1%) patients experienced SEMS-related perforations (perforation group), with 21 instances classified as overt and four as silent perforations. Compared with 125 matched controls (non-perforation group), the perforation group showed elevated rates of emergent surgery, open surgery, and stoma formation, as well as a reduced interval from SEMS placement to surgery. The 5-year recurrence rate was notably higher in the perforation group than in the no-perforation group (47.4% vs. 21.5%, p < 0.001), whereas the 5-year survival rate was not significantly different between groups (63.8% vs. 80.0%, p = 0.330). Conclusions SEMS-related perforation led to less favorable surgical outcomes and a higher rate of recurrence, although no notable impact on overall survival was observed. Considering the risk of perforation, these findings support the cautious use of SEMS as a bridge to surgery.


  • Open Access

    Mitochondria Derived From iPSCs Control by Reciprocal Regulation of Th17/Treg and Anti-Fibrosis

    by Jin Seok Woo, Hanbi Lee, JooYeon Jhun, SeungCheon Yang, Yeon Su Lee, Yoo-Jin Shin, Sun Woo Lim, Bo-In Lee, Chul Woo Yang, Byung Ha Chung, et al.

    Woo JS, et al. Immune Netw. 2025 Dec;25(6):e41. https://doi.org/10.4110/in.2025.25.e41


  • Open Access

    Development of colonic stent simulator using three-dimensional printing technique: a simulator development study in Korea

    by Hyundam Gu, Suyoung Lee, Sol Kim, Hye-Lim Jang, Da-Woon Choi, Kyu Seok Kim, Yu Ri Shin, Dae Young Cheung, Bo-In Lee, Jin Il Kim, et al.

    Background/Aims: Colonic stenting plays a vital role in the management of acute malignant colonic obstruction. The increasing use of self-expandable metal stents (SEMS) and the diverse challenges posed by colonic obstruction at various locations underscore the importance of effective training for colonic stent placement.Methods: All the components of the simulator were manufactured using silicone molding techniques in conjunction with three-dimensional (3D) printing. 3D images sourced from computed tomography scans and colonoscopy images were converted into a stereolithography format. Acrylonitrile butadiene styrene copolymers have been used in fused deposition modeling to produce moldings.Results: The simulator replicated the large intestine from the rectum to the cecum, mimicking the texture and shape of the human colon. It enables training for colonoscopy insertion, cecum intubation, loop reduction, and stenting within stenotic areas. Interchangeable stenotic modules for four sites (rectum, sigmoid colon, descending colon, and ascending colon) were easily assembled for training. These modules integrate tumor contours and blood vessel structures with a translucent center, allowing real-time visualization during stenting. Successful and repeatable demonstrations of stent insertion and expansion using the reusable SEMS were consistently achieved.Conclusions: This innovative simulator offers a secure colonic stenting practice across various locations, potentially enhancing clinical outcomes by improving operator proficiency during actual procedures.


  • Open Access

    Is endoscopic hemostasis safe and effective for delayed post-polypectomy bleeding?

    by Jae-Yong Cho, Yunho Jung, Han Hee Lee, Jung-Wook Kim, Kee Myung Lee, Hyun Lim, Geun-Hyuk Choi, Seong Woo Choi, Bo-In Lee

    Jae-Yong Cho, Yunho Jung, Han Hee Lee, Jung-Wook Kim, Kee Myung Lee, Hyun Lim, Geun-Hyuk Choi, Seong Woo Choi, and Bo-In Lee. Int J Gastrointest Interv 2024;13:122-7. https://doi.org/10.18528/ijgii240067